Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Retained Earnings (2018 - 2025)

Historic Retained Earnings for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to -$5.4 million.

  • BioNexus Gene Lab's Retained Earnings fell 7422.71% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.4 million, marking a year-over-year decrease of 7422.71%. This contributed to the annual value of -$3.4 million for FY2024, which is 8666.49% down from last year.
  • Latest data reveals that BioNexus Gene Lab reported Retained Earnings of -$5.4 million as of Q3 2025, which was down 7422.71% from -$4.7 million recorded in Q2 2025.
  • BioNexus Gene Lab's Retained Earnings' 5-year high stood at $1.5 million during Q1 2022, with a 5-year trough of -$5.4 million in Q3 2025.
  • For the 5-year period, BioNexus Gene Lab's Retained Earnings averaged around -$817385.2, with its median value being $828075.0 (2023).
  • In the last 5 years, BioNexus Gene Lab's Retained Earnings surged by 38839.1% in 2021 and then tumbled by 31120.44% in 2024.
  • Over the past 5 years, BioNexus Gene Lab's Retained Earnings (Quarter) stood at $1.5 million in 2021, then dropped by 23.54% to $1.2 million in 2022, then plummeted by 259.49% to -$1.8 million in 2023, then plummeted by 86.66% to -$3.4 million in 2024, then plummeted by 56.6% to -$5.4 million in 2025.
  • Its Retained Earnings stands at -$5.4 million for Q3 2025, versus -$4.7 million for Q2 2025 and -$4.1 million for Q1 2025.